Home › NDC Lookup › RxCUI directory › RxCUI 1810582

10 ML eteplirsen 50 MG/ML Injection [Exondys] — RxCUI 1810582

Name: 10 ML eteplirsen 50 MG/ML Injection [Exondys] (RxCUI 1810582)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1810582 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1810582

Official name10 ML eteplirsen 50 MG/ML Injection [Exondys]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as10 ML Exondys 50 MG/ML Injection; Exondys 51, 500 MG in 10 ML Injection; Exondys 500 MG per 10 ML Injection

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)7,465 prescriptions · 27 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How 10 ML eteplirsen 50 MG/ML Injection [Exondys] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 10 ML eteplirsen 50 MG/ML Injection [Exondys] RxCUI 1810582 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Eteplirsen 1810569 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Exondys 1810574 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Eteplirsen Injection 1810572 SCDF
- Eteplirsen Injectable Product 1810571 SCDG
- Eteplirsen Injection [Exondys] 1810576 SBDF
- Exondys Injectable Product 1810577 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 10 ML eteplirsen 50 MG/ML Injection 1810581 SCD
- Eteplirsen 50 MG/ML 1810570 SCDC
- Eteplirsen 50 MG/ML [Exondys] 1810575 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

10 ML eteplirsen 50 MG/ML Injection SCD · 1810581
Eteplirsen 50 MG/ML SCDC · 1810570
Eteplirsen Injection SCDF · 1810572
Eteplirsen Injectable Product SCDG · 1810571

Brand-Name Concepts

Eteplirsen 50 MG/ML [Exondys] SBDC · 1810575
Eteplirsen Injection [Exondys] SBDF · 1810576
Exondys Injectable Product SBDG · 1810577
Exondys BN · 1810574

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 1810582 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
60923-0284-10	1 VIAL, SINGLE-USE in 1 CARTON (60923-284-10) / 10 mL in 1...	Exondys 51	Sarepta Therapeutics, Inc.	2016-09-19
60923-0363-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-363-02) / 2 mL in 1 V...	Exondys 51	Sarepta Therapeutics, Inc.	2016-09-19

Observed labelers: Sarepta Therapeutics, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.